Literature DB >> 25081541

Reversed expression of GRIM-1 and GRP78 in human non-small cell lung cancer.

Hui-Mei Wu1, Zi-Feng Jiang1, Xiao-Yun Fan1, Tong Wang1, Xue-Bo Yan1, Yang Ma2, Wei-Hua Xiao2, Rong-Yu Liu3.   

Abstract

Gene associated with retinoid and interferon-induced mortality 1 (GRIM-1) acts as a tumor growth suppressor via apoptosis induction. However, GRIM-1 expression in human non-small cell lung cancer (NSCLC) and its potential interaction with another apoptosis-associated protein-glucose-regulated protein 78 (GRP78)-are as yet unknown. Using 40 surgical specimens, we showed significantly lower expression of GRIM-1 in NSCLC at both protein and messenger RNA (mRNA) levels compared with that in normal tissues (P < .01 and P < .001, respectively). Interestingly, these tumors tended to express higher basal amounts of GRP78 protein and mRNA (P < .05 and P < .001, respectively). Similarly, in the NSCLC tissues, weaker staining for GRIM-1 (main intensity + to ++) but stronger staining for GRP78 (main intensity +++ to ++++) was observed. Correlation analysis showed that protein and mRNA expression or the percentage of cells immunoreactive for GRIM-1 was negatively correlated with that of GRP78 (r = -0.279, r = -0.326, or r = -0.571, respectively). Coimmunoprecipitation and transient transfection revealed that GRIM-1 interacted with GRP78 and suppressed GRP78 protein expression. In addition, there was no correlation between GRIM-1 expression and clinical characteristics, whereas GRP78 expression was significantly correlated with tumor-nodes-metastasis (TNM) stage (stage 3 + 4 versus stage 1 + 2). In conclusion, the expression of GRIM-1 and GRP78 was negatively correlated in human NSCLC tissues, and the down-regulation of GRP78 by GRIM-1 provides a possible mechanism for their interaction. This study suggests a novel potential molecular pathway inactivated during the development of NSCLC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GRIM-1; GRP78; Interaction; Non–small cell lung cancer; Pathogenesis

Mesh:

Substances:

Year:  2014        PMID: 25081541     DOI: 10.1016/j.humpath.2014.04.023

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

1.  DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer.

Authors:  Xianliang Chen; Xiaoying Guan; Huiyu Zhang; Xiaobin Xie; Hongyan Wang; Jie Long; Tonghui Cai; Shuhua Li; Zhen Liu; Yajie Zhang
Journal:  J Exp Clin Cancer Res       Date:  2015-01-22

2.  Knockout of MARCH2 inhibits the growth of HCT116 colon cancer cells by inducing endoplasmic reticulum stress.

Authors:  Dan Xia; Wanli Ji; Chentong Xu; Xin Lin; Xiaokun Wang; Yan Xia; Ping Lv; Quansheng Song; Dalong Ma; Yingyu Chen
Journal:  Cell Death Dis       Date:  2017-07-27       Impact factor: 8.469

3.  SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival.

Authors:  Hexiu Su; Juncheng Hu; Liang Huang; Yang Yang; Morgan Thenoz; Anna Kuchmiy; Yufeng Hu; Peng Li; Hui Feng; Yu Zhou; Tom Taghon; Pieter Van Vlierberghe; Guoliang Qing; Zhichao Chen; Hudan Liu
Journal:  Nat Commun       Date:  2018-10-15       Impact factor: 14.919

4.  Integrated quantitative proteomic and transcriptomic analysis of lung tumor and control tissue: a lung cancer showcase.

Authors:  Stefan Tenzer; Petra Leidinger; Christina Backes; Hanno Huwer; Andreas Hildebrandt; Hans-Peter Lenhof; Tanja Wesse; Andre Franke; Eckart Meese; Andreas Keller
Journal:  Oncotarget       Date:  2016-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.